Quattro Financial Advisors LLC Acquires 94,971 Shares of Pfizer Inc. (NYSE:PFE)

Quattro Financial Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 327,486.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,000 shares of the biopharmaceutical company’s stock after purchasing an additional 94,971 shares during the period. Pfizer accounts for about 0.7% of Quattro Financial Advisors LLC’s portfolio, making the stock its 29th biggest position. Quattro Financial Advisors LLC’s holdings in Pfizer were worth $2,636,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.4 %

Shares of PFE traded down $0.39 during mid-day trading on Tuesday, reaching $27.83. The company had a trading volume of 21,710,519 shares, compared to its average volume of 40,642,027. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a 50-day moving average price of $27.93 and a 200 day moving average price of $27.70. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a market capitalization of $157.70 billion, a price-to-earnings ratio of -464.76, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PFE. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, June 26th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Morgan Stanley raised their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.